Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

Somatic mutations in EGFR (exons 19 and 21) and KRAS (exon 2) are found in lung adenocarcinomas and have potential prognostic value in patients with advanced disease. These mutations also have therapeutic significance, as they predict for sensitivity and resistance, respectively, to EGFR tyrosine ki...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thoracic oncology 2008-02, Vol.3 (2), p.111-116
Hauptverfasser:	Marks, Jenifer L., Broderick, Stephen, Zhou, Qin, Chitale, Dhananjay, Li, Allan R., Zakowski, Maureen F., Kris, Mark G., Rusch, Valerie W., Azzoli, Christopher G., Seshan, Venkatraman E., Ladanyi, Marc, Pao, William
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - pathology Adenocarcinoma - surgery Adult Aged Aged, 80 and over Chemotherapy, Adjuvant Drug Resistance, Neoplasm - genetics EGFR and KRAS mutations Female Genes, ras Humans Lung adenocarcinoma Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Lung Neoplasms - surgery Male Middle Aged Mutation Prognosis Protein Kinase Inhibitors - pharmacology Receptor, Epidermal Growth Factor - genetics Surgery Survival after resection Survival Analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!